AstraZeneca fell more than 5% on Monday after the company revealed that it would acquire rare-disease specialist Alexion in a $39 billion deal.
Editorial use only Contact your sales representative for commercial and promotional uses.License this clip
More footage filed by NurPhoto videographers.